2025 AHA | Dose-Dependent and Sustained Reduction in Lipoprotein(a) Level after a Single Dose of Kylo-11, an LPA-targeted Small Interfering RNA, in Healthy Volunteers: A First-in-Human Phase I Study

2025 AHA | Dose-Dependent and Sustained Reduction in Lipoprotein(a) Level after a Single Dose of Kylo-11, an LPA-targeted Small Interfering RNA, in Healthy Volunteers: A First-in-Human Phase I Study

HANGZHOU, China – November [11], 2025 – Hygieia Pharmaceuticals (referring to “Hygieia” thereafter), a clinical-stage biotech company dedicated to developing RNAi medicines, today announced that the preliminary results from the first-in-human Phase I study (NCT06363851) of Kylo-11 (an experimental small interfering RNA medicine targeting LPA mRNA) in healthy volunteers with elevated serum Lp(a) level. The data were presented in an oral presentation at the American Heart Association (AHA) Scientific Sessions in New Orleans, Louisiana (Abstract ID: 4390197).

11

2025

/

11

Hygieia Pharmaceuticals Announces First Patient dosed in a US/CN Multi-Center Phase II Clinical Trial Investigating a Long-acting Small Interfering RNA (siRNA) Therapy (Kylo-11) Designed to Lower the Production of Lipoprotein(a) [Lp(a)]

Hygieia Pharmaceuticals Announces First Patient dosed in a US/CN Multi-Center Phase II Clinical Trial Investigating a Long-acting Small Interfering RNA (siRNA) Therapy (Kylo-11) Designed to Lower the Production of Lipoprotein(a) [Lp(a)]

HANGZHOU, China – October [30], 2025 – Hygieia Pharmaceuticals (“Hygieia”, or the “Company”), a clinical-stage biopharmaceutical company today announces that the first patient has been dosed at Peking University First Hospital in an international US/CN multi-center Phase II clinical trial investigating Kylo-11, a small interfering RNA (siRNA) program designed to lower serum lipoprotein(a) [Lp(a)], an important risk factor for cardiovascular diseases. This study will be conducted in both China and the United States.

30

2025

/

10

Hygieia Pharmaceuticals completes A2 round of financing to rapidly promote clinical development of multiple siRNA pipelines

Hygieia Pharmaceuticals completes A2 round of financing to rapidly promote clinical development of multiple siRNA pipelines

Recently, Hygieia Pharmaceuticals Co., Ltd. (hereinafter referred to as "Hygieia ") announced that it has completed tens of millions of yuan in A2 round financing, led by Huangpu Biomedicine Industry Investment Fund Management and followed by Nanwan Baiao Fund.

04

2024

/

09

< 1 >
Picture Name

Business cooperation:bd@hygieiapharma.com

No. 18, Lane 2777, Jinxiu East Road, Pudong New Area, Shanghai

Room 802, Building 21, Hexiang Technology Center, Xiasha Street, Qiantang District, Hangzhou City, Zhejiang Province, China

©2024 Hygieia Pharmaceuticals Co., Ltd. All Rights Reserved

Website construction:www.300.cn   SEO